## ARWR: Arrowhead Pharmaceuticals, Inc. - XLV: Healthcare

### Executive Summary

PARABOLIC warning: MRS_10 at 21.4% exceeds exhaustion threshold (8.0%). Extreme momentum typically precedes mean reversion. Consider profit-taking or tight stops.

- **Horizon:** 1-5 days (momentum)
- **Risk Profile:** High - extreme momentum reversal risk
- **Stop Type:** Fixed 2xATR ($56.86)
- **If Wrong:** Exit on momentum reversal or stop hit
- **Invalidation:** MRS_10 drops below exhaustion threshold

### News

- **Articles:** 5
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia**
- Source: Yahoo Finance | 20251202T073000 | Bullish | Relevance: 100%
- Arrowhead Pharmaceuticals announced that its investigational drug, plozasiran, has received FDA Breakthrough Therapy designation for severe hypertriglyceridemia (SHTG). This designation accelerates the development and review of drugs for serious conditions where preliminary evidence shows substantial improvement over existing therapies. Plozasiran aims to reduce triglyceride levels in adults with SHTG, a condition with limited treatment options that significantly increases the risk of acute pancreatitis.

**2. Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences**
- Source: Business Wire | 20251202T050228 | Somewhat-Bullish | Relevance: 100%
- Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced its participation in several December 2025 events, including the Piper Sandler and Evercore Healthcare Conferences where they will hold fireside chats. The company will also present at the World Congress of Insulin Resistance, Diabetes and Cardiovascular Disease and the CNS Delivery Summit, highlighting their plozasiran studies and TRiMâ„¢ platform. Presentation materials will be available on their investor relations website.

**3. HC Wainwright & Co. Maintains Arrowhead Pharmaceuticals (ARWR) Buy Recommendation**
- Source: Nasdaq | 20251203T050229 | Neutral | Relevance: 100%
- HC Wainwright & Co. has reiterated a Buy recommendation for Arrowhead Pharmaceuticals (ARWR) with an average one-year price target of $50.53/share, despite a projected decrease of 10.17% from its current price. The company's projected annual revenue is 410MM, a 50.51% decrease, and the non-GAAP EPS is expected to be -1.33. Institutional ownership of ARWR increased by 4.57% to 130,072K shares, and the put/call ratio of 0.32 suggests a bullish outlook.

**4. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Catapults 33% Though Its Price And Business Still Lag The Industry**
- Source: Simply Wall Street | 20251203T050228 | Somewhat-Bearish | Relevance: 100%
- Arrowhead Pharmaceuticals (NASDAQ:ARWR) saw a 33% stock increase last month, culminating in a 116% rise over the past year, yet its price-to-sales (P/S) ratio of 9.2x remains below the industry average. Despite strong past revenue growth, future revenue is projected to contract by 14% annually, contrasting sharply with the broader biotech industry's anticipated 128% annual expansion. This outlook contributes to its modest P/S ratio, suggesting investors are cautious about future growth prospects.

**5. Arrowhead Pharmaceuticals Poised for Growth Following Breakthrough FDA Approvals**
- Source: StocksToTrade | 20251204T050229 | Bullish | Relevance: 96%
- Arrowhead Pharmaceuticals (ARWR) has seen significant growth following breakthroughs including an FDA Breakthrough Therapy designation for plozasiran and a milestone payment from Sarepta. The company reported a substantial revenue increase to $829.4M and a net profit of $30.1M, reversing previous losses. These developments, along with strategic collaborations, have boosted investor confidence and analyst price targets, positioning ARWR for continued expansion in the biopharmaceutical sector.

### Analyst Activity

**Target Signal:** VERY_BULLISH (Raises: 7, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | HC Wainwright & | $85 | $80 | +6% |
| 2025-12-01 | B of A Securiti | $62 | $42 | +48% |
| 2025-12-01 | Chardan Capital | $60 | $60 | 0% |
| 2025-11-26 | Morgan Stanley | $48 | $45 | +7% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | HC Wainwright & | main | Buy |
| 2025-12-01 | B of A Securiti | main | Buy |
| 2025-12-01 | Chardan Capital | main | Buy |
| 2025-11-26 | Morgan Stanley | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 8 ($0.00M) |
| Sells | 5 ($3.67M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 54.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 1 |

**Top Holders:**
- Blackrock Inc.: 14.9% (+4.1%)
- Vanguard Group Inc: 11.8% (+3.3%)
- Avoro Capital Adviso: 8.0% (+2.8%)
- State Street Corpora: 4.7% (+0.4%)
- FMR, LLC: 4.2% (+11.4%)

### Key Risks

1. Insider selling cluster: $3.7M in recent transactions.
2. Elevated short interest (9.8%): bears positioning against stock.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 7 raises (avg +38%) could attract flows.
- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_10 improving +4.8% over 5 days suggests accumulation.

### Fundamentals

Balance sheet: strong liquidity (4.9x). Revenue declining -31% YoY, concerning. Analyst sentiment positive (7 raises, avg +38%). Insider selling cluster ($3.7M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 1 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.7B |
| Beta | 1.29 |
| 52W Range | $9.57 - $72.36 |
| Short Interest | 9.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -1.32 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 strengthening from 16.6% to 21.4% (+4.8% in 5 days), confirming momentum buildup. Extended beyond STRENGTH zone (21.4% > 6.0%), caution on chasing. MRS_5 at 8.5% confirms short-term momentum alignment. Outperforming sector by 22.8pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (2.25), confirming momentum. RSI overbought at 78, risk of mean reversion. OFD pattern: +DUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 21.36% (CS: 100) | Strong |
| RSI_14 | 77.8 | Overbought |
| MACD Histogram | 2.25 | Bullish |
| vs SMA20 | 1.394x | Above |
| vs SMA50 | 1.580x | Above |
| vs SMA200 | 2.769x | Above |

### Decision

- **Verdict:** SELL
- **Thesis:** PARABOLIC

### Trade Setup

- **Entry:** $64.66
- **Stop Loss:** $56.86 (12.1% risk)
- **Target:** $72.46 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** PARABOLIC thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 64
- **Position Value:** $4,138.24
- **Portfolio %:** 4.14%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-09 (Est: $-0.10)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-0.16 | $-0.18 | -14.4% |
| 2025Q2 | $-1.10 | $-1.26 | -14.4% |
| 2025Q1 | $-0.46 | $2.75 | +695.0% |
| 2024Q4 | $-0.72 | $-1.39 | -92.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*